




Topiramate ER Prior Authorization

Drug Applied:	topiramate ER capsules
---------------	------------------------

Criteria:

Drug Applied will be approved when the requested medication is being used for a compendia-supported indication and all of the following criteria are met:

I. Initial Therapy Criteria

A. Epilepsy

1. Diagnosis includes one of the following:

- a) Partial-onset seizures
- b) Primary generalized tonic-clonic seizures
- c) Seizures associated with Lennox-Gastaut syndrome, adjunctive treatment

Approval Duration: 12 months

B. Migraine prevention

1. Used for preventive treatment of migraine

Approval Duration: 12 months

C. Compendia-supported indications

1. Chart notes and/or prescriber do **not** indicate that patient is using the requested agent for weight loss

Approval Duration: 12 months

II. Continued Therapy Criteria


A. FDA approved and compendia-supported indication

1. Chart notes and/or prescriber do **not** indicate that patient is using the requested agent for weight loss

Approval Duration: 12 months

References:

- 1. Topiramate extended-release capsules prescribing Information. Teva Pharmaceuticals, Inc. March 2026.
- 2. Qudexy XR- topiramate capsule, extended release prescribing Information. Upsher-Smith Laboratories, LLC. March 2026.



3. Chung SS. A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures. *Ther Adv Neurol Disord*. 2015 May;8(3):131-6. PMID: 25941540. [Link](#).
4. Lambrecht L, Braun T, Todd W, Halvorsen M. Switching between Immediate- and Extended-Release Formulations Does Not Affect the Steady-State Pharmacokinetic Profile of Topiramate. *Neurology* 2012 Apr. 78 (1_supplement) P06.112. [Link](#).
5. Bialer M, Shekh-Ahmad T, Braun TL, Halvorsen MB. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. *Epilepsia*. 2013 Aug;54(8):1444-52. PMID: 23692553. [Link](#).
6. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. *Epilepsy Behav*. 2002 Aug;3(4):338-342. PMID: 12609331. [Link](#).
7. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. *Epilepsia*. 2008 Mar;49(3):446-54. PMID: 18031549. [Link](#).

Policy Owned by: PBM team